Analysts Set LifeStance Health Group, Inc. (NASDAQ:LFST) Price Target at $8.42

Key Points

• LifeStance Health Group, Inc. has received a consensus rating of "Moderate Buy" from analysts, with one sell recommendation, five buy recommendations, and one strong buy.
• The average price objective set by analysts for the stock is $8.42, with recent upgrades by UBS Group and BTIG Research.
• Institutional investors own 85.50% of LifeStance Health Group’s stock, highlighting significant institutional interest and investment in the company.

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) have earned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.4167.

Several research firms have recently weighed in on LFST. UBS Group upgraded LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 price objective on the stock in a research note on Tuesday, May 27th. BTIG Research started coverage on LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 target price on the stock.

LifeStance Health Group Stock Down 1.0%

LFST stock traded down $0.04 during mid-day trading on Wednesday, hitting $3.86. 5,051,027 shares of the company were exchanged, compared to its average volume of 1,877,946. The company has a market capitalization of $1.50 billion, a PE ratio of -38.60 and a beta of 1.13. The firm has a fifty day simple moving average of $4.84 and a 200 day simple moving average of $6.25. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $8.61.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative return on equity of 2.47% and a negative net margin of 2.78%. The business had revenue of $345.31 million during the quarter, compared to the consensus estimate of $345.05 million. During the same period in the prior year, the business posted ($0.06) earnings per share. LifeStance Health Group's revenue was up 10.6% compared to the same quarter last year. On average, research analysts forecast that LifeStance Health Group will post -0.18 earnings per share for the current fiscal year.

Insider Buying and Selling at LifeStance Health Group

In related news, insider Ujjwal Ramtekkar sold 16,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total value of $95,040.00. Following the completion of the transaction, the insider owned 113,435 shares of the company's stock, valued at $673,803.90. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 3.20% of the company's stock.

Hedge Funds Weigh In On LifeStance Health Group

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in LifeStance Health Group by 5.0% in the first quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company's stock valued at $74,733,000 after purchasing an additional 531,841 shares during the period. Jennison Associates LLC boosted its position in shares of LifeStance Health Group by 2.1% during the 1st quarter. Jennison Associates LLC now owns 8,255,236 shares of the company's stock worth $54,980,000 after purchasing an additional 168,856 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of LifeStance Health Group by 2.3% in the 1st quarter. Wellington Management Group LLP now owns 5,399,293 shares of the company's stock valued at $35,959,000 after buying an additional 123,056 shares during the period. Dimensional Fund Advisors LP increased its position in LifeStance Health Group by 87.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock valued at $25,977,000 after buying an additional 1,643,390 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in LifeStance Health Group by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,465,471 shares of the company's stock worth $25,546,000 after acquiring an additional 13,293 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.